OR WAIT null SECS
Brings extensive experience in enterprise technology to rapidly expanding Chicago-based clinical software company
Chicago, IL – March 19, 2009 – ClearTrial, a leading provider of clinical trial software for clinical trial operations planning, budgeting, and outsourcing, announced today that Michael Bruns, formerly Director of the Technology Investment Banking Group at Robert W. Baird, has joined the company as Chief Operating Officer. A 17-year veteran in enterprise software and information technology markets, Bruns brings extensive experience in corporate strategy, operations, and business development to ClearTrial.
As Chief Operating Officer, Bruns will be responsible for the company's global operations and help further develop and implement the company's growth strategy. He will oversee finance, operations, and the expansion of ClearTrial's global sales, services, and engineering organizations.
"Michael Bruns has a consistent track record of accelerating growth in enterprise software companies," noted ClearTrial CEO Mike Soenen. "His experience and skills will help drive ClearTrial's revenue growth and further cement our market leadership as we assist life sciences companies in bringing new, quality treatments to market faster, at a lower cost and with fewer resources – a critical advantage in today's market."
Prior to joining ClearTrial, Bruns founded and directed the Technology Investment Banking group at Robert W. Baird & Co., a global investment banking firm. He led the group's business development efforts and advised executive management teams and boards of directors of public and private company clients on corporate strategy, acquisition strategy, and corporate finance alternatives. Previously, Bruns was Vice President of Mergers & Acquisitions for Broadview International, LLC (now Jefferies Broadview), where he conducted strategic positioning and transaction development for enterprise software and communications technology clients.
Bruns has extensive software development and systems integration experience, having been a principal at Waterstone Consulting, LLC – a provider of complex pricing and contract management software solutions to Fortune 2000 life sciences, manufacturing, and distribution companies – and a senior consultant with Accenture. He holds a BBA in Finance from the University of Michigan, and an MBA from Harvard Business School.
"ClearTrial has all the elements in place to continue to rapidly expand market share," observed Bruns. "Our award-winning software solution brings real business value to a well-established and growing customer base, and we have a great team in place as the foundation for future growth. I'm looking forward to helping ClearTrial continue to expand our leadership in the clinical software market."
ClearTrial® is a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing. ClearTrial's award-winning software helps pharmaceutical, biotechnology, medical device companies, and CROs expedite the clinical development process without sacrificing quality of results. The company’s software products support clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit http://www.cleartrial.com.
ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.